Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
The present application discloses compositions and methods of synthesis and use of 18 F- or 19 F-labeled molecules of use in PET, SPECT and/or MR imaging. Preferably, the 18 F or 19 F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a bifunctional chelating agent, which may then be directly or indirectly attached to the targeting molecule. In other embodiments, the 18 F or 19 F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. The disclosed methods and compositions allow the simple and reproducible labeling of molecules at very high efficiency and specific activity in 30 minutes or less. In preferred embodiments, the bifunctional chelating agent bound to 18 F- or 19 F-metal complex may be conjugated to the molecule to be labeled at a reduced temperature, e.g. room temperature.
1. A method of labeling a molecule with 18 F or 19 F comprising
a) attaching a complex of 18 F or 19 F and a group IIIA metal to a bifunctional chelating agent; and
b) attaching the bifunctional chelating agent to the molecule to form an 18 F- or 19 F-labeled molecule.
2. The method of claim 1 , wherein the 18 F-metal or 19 F-metal complex is attached to the bifunctional chelating agent at a temperature between 90° C. and 110° C.
3. The method of claim 1 , wherein the bifunctional chelating agent is attached to the molecule at room temperature.
4. The method of claim 1 , wherein the bifunctional chelating agent is selected from the group consisting of NODA-BA, NODA-BAEM, NODA-BM, NODA-butyne, NODA-EA, NODA-EBA, NODA-EPA, NODA-EPN, NODA-HA, NODA-MBA, NODA-MBEM, NODA-MPAA, NODA-MPAA NHS ester, NDOA-MPAEM, NODA-MPAPEG 3 M 3 , NODA-MPH, NODA-MPN, NODA-2-nitroimidazole, NODA-PA, NODA-PAEM and NODA-propyl amine.
5. The method of claim 1 , wherein the molecule is selected from the group consisting of a protein, a peptide, an antibody, a monoclonal antibody, a bispecific antibody, a multispecific antibody, an antibody fusion protein, an antigen-binding antibody fragment, an affibody and a targetable construct.
6. The method of claim 1 , wherein the group IIIA metal is aluminum.
7. The method of claim 1 , wherein the aluminum is attached to the bifunctional chelating agent before the 18 F or 19 F is complexed to the aluminum.
8. The method of claim 1 , wherein a metal- 18 F or metal- 19 F complex is attached to the bifunctional chelating agent by heating in an aqueous medium at a temperature between 50 ° C. and 110° C.
9. The method of claim 1 , wherein the efficiency of labeling with 18 F is at least 35% at 50° C.
10. The method of claim 1 , wherein the specific activity of the labeled molecule is at least 4,000 Ci/mmol.
11. The method of claim 1 , wherein a metal- 18 F or metal- 19 F complex is attached to the bifunctional chelating agent in an aqueous medium comprising aluminum, trehalose, potassium biphthalate, ethanol and ascorbic acid at a pH between 3.9 and 4.2.
12. The method of claim 1 , wherein multiple copies of the bifunctional chelating agent are attached to the molecule.
13. The method of claim 1 , wherein the 18 F- or 19 F-labeled molecule is produced in less than 30 minutes from the start of the method.
14. A method of imaging the distribution of 18 F- or 19 F-labeled molecules comprising:
a) attaching a complex of 18 F or 19 F and a group IIIA metal to a bifunctional chelating agent;
b) attaching the bifunctional chelating agent to the molecule to form an 18 F- or 19 F-labeled molecule;
c) administering the 18 F- or 19 F-labeled molecule to a subject; and
d) using positron emission tomography (PET), magnetic resonance imaging (MRI) and/or single photon emission computer tomography (SPECT) to image the distribution of the labeled molecule in the subject.
15. The method of claim 1 , wherein the bifunctional chelating agent is attached to the molecule by a click chemistry reaction or by a maleimide-suithydryl reaction.
16. The method of claim 1 , wherein the yield of labeled molecule is at least 95%.
17. The method of claim 14 , further comprising:
e) analyzing the distribution of the labeled molecule to detect, diagnose or image the presence of a disease in the subject, wherein the disease is selected from the group consisting of cancer, a cardiovascular disease, an infectious disease, an inflammatory disease, an autoimmune disease, an immune dysfunction disease, graft versus host disease, organ transplant rejection and a neurological disease.
18. The method of claim 17 , wherein the labeled molecule binds to an antigen selected from the group consisting of carbonic anhydrase IX, CCCL19, CCCL21, CSAp, CD1, CD1a, CD2, CD3, CD4, CD5, CD8, CD11A, CD14, CD15, CD16, CD18, CD19, IGF-1R, CD20, CD21, CD22, CD23, CD25, CD29, CD30, CD32b, CD33, CD37, CD38, CD40,CD40L, CD45, CD46, CD52, CD54, CD55, CD59, CD64, CD66a-e, CD67, CD70, CD74, CD79a, CD80, CD83, CD95, CD126, CD133, CD138, CD147, CD154, CXCR4, CXCR7, CXCL12, HIF-1α, AFP, PSMA, CEACAM5, CEACAM-6, c-met, B7, ED-B of fibronectin, Factor H, FHL-1, Flt-3, folate receptor, GRO-β, HMGB-1, hypoxia inducible factor (HIF), HM1.24, insulin-like growth factor-1 (ILGF-1), IFN-γ, IFN-α, IFN-β, IL-2, IL-4R, IL-6R, IL-13R, IL-15R, IL-17R, IL-18R,IL-6, IL-8, IL-12, IL-15, IL-17, IL-18, IL-25, IP-10, MAGE, mCRP, MCP-1, MIP-1A, MIP-1B, MIF, MUC1, MUC2, MUC3, MUC4, MUC5, NCA-95, NCA-90, Ia, HM1.24, EGP-1, EGP-2, HLA-DR, tenascin, Le(y), RANTES, T 101 , TAC, Tn antigen, Thomson-Friedenreich antigens, tumor necrosis antigens, TNF-α, TRAIL receptor (R1 and R2), VEGFR, EGFR, PIGF, complement factors C3, C3a, C3b, C5a, and C5.
19. The method of claim 17 , wherein the infectious disease is infection with a pathogen selected from the group consisting of fungi, viruses, parasites, bacteria, human immunodeficiency virus (HIV), herpes virus, cytomegalovirus, rabies virus, influenza virus, hepatitis B virus, Sendai virus, feline leukemia virus, Reovirus, polio virus, human serum parvo-like virus, simian virus 40, respiratory syncytial virus, mouse mammary tumor virus, Varicella-Zoster virus, Dengue virus, rubella virus, measles virus, adenovirus, human T-cell leukemia viruses, Epstein-Barr virus, murine leukemia virus, mumps virus, vesicular stomatitis virus, Sindbis virus, lymphocytic choriomeningitis virus, wart virus, blue tongue virus, Streptococcus agalactiae, Legionella pneumophila, Streptococcus pyogenes, Escherichia coli, Neisseria gonorrhoeae, Neisseria meningitidis, Pneumococcus, Hemophilus influenzae B, Treponema pallidum , Lyme disease spirochetes, Pseudomonas aeruginosa, Mycobacterium leprae, Brucella abortus, Mycobacterium tuberculosis and Clostridium tetani.
20. The method of claim 17 , wherein the autoimmune disease is selected from the group consisting of immune-mediated thrombocytopenia, acute idiopathic thrombocytopenic purpura, chronic idiopathic thrombocytopenic purpura, dermatomyositis, Sjogren's syndrome, multiple sclerosis, Sydenham's chorea, myasthenia gravis, systemic lupus erythematosus, lupus nephritis, rheumatic fever, polyglandular syndromes, bullous pemphigoid, diabetes mellitus, Henoch-Schonlein purpura, post-streptococcal nephritis, erythema nodosum, Takayasu's arteritis, Addison's disease, rheumatoid arthritis, sarcoidosis, ulcerative colitis, erythema multiforme, IgA nephropathy, polyarteritis nodosa, ankylosing spondylitis, Goodpasture's syndrome, thromboangitis obliterans, primary biliary cirrhosis, Hashimoto's thyroiditis, thyrotoxicosis, scleroderma, chronic active hepatitis, polymyositis/dermatomyositis, polychondritis, pemphigus vulgaris, Wegener's granulomatosis, membranous nephropathy, amyotrophic lateral sclerosis, tabes dorsalis, giant cell arteritis/polymyalgia, pernicious anemia, rapidly progressive glomerulonephritis and fibrosing alveolitis.
21. The method of claim 17 , wherein the labeled molecule is an antibody selected from the group consisting of hR1 (anti-IGF-1R), hPAM4 (anti-pancreatic cancer mucin), hA20 (anti-CD20), hA19 (anti-CD19), hIMMU31 (anti-AFP), hLL1 (anti-CD74), hLL2 (anti-CD22), hMu-9 (anti-CSAp), hL243 (anti-HLA-DR), hMN-14 (anti-CEACAM5), hMN-15 (anti-CEACAM6), hRS7 (anti-EGP-1) and hMN-3 (anti-CEACAM6).
22. The method of claim 1 , wherein the bifunctional chelating agent is conjugated to a molecule via an amide, ester, anhydride, carbonate, carbamate, dithiocarbamate, ether, thioether, disulfide, urea, thiourea, triazoyl, amine, imine, oxime or hydrazone bond.
23. The method of claim 1 , wherein the molecule is selected from the group consisting of oligonucleotides, hormones, growth factors, cytokines, chemokines, angiogenic factors, anti-angiogenic factors, immunomodulators, peptides, polypeptides, proteins, nucleic acids, antibodies, antibody fragments, interleukins, interferons, oligosaccharides, polysaccharides, lipids, siderophores and vitamins.
24. The method of claim 1 , wherein the molecule is an antibody, somatostatin, EGF, VEGF, bombesin, methotrexate, growth hormone, prostate cancer specific antibody, breast cancer specific antibody, RGD, folic acid, a folic acid derivative or analog thereof.
25. The method of claim 1 , wherein the labeled molecule is used for positron emission tomography (PET), functional magnetic resonance imaging (MRI) and/or single photon emission computer tomography (SPECT).
26. The method of claim 1 , wherein the bifunctional chelating agent is selected from the group consisting of NODA-MPAEM, NODA-MPAA, NODA-EPN, NODA-MPN, NODA-HA, NODA-MBA, NODA-EBA, NODA-Butyne, NODA-BA, NODA-BAEM, NODA-PM, NODA-PAEM, NODA-PI, NODA-MPI, and NODA-MPAA NHS ester.
27. The method of claim 1 , wherein the 18 F-metal or 19 F-metal complex is attached to the bifunctional chelating agent in the presence of an organic solvent selected from the group consisting of ethanol, acetonitrile, MeCN, DMF and THF.
28. The method of claim 1 , wherein the molecule is selected from the group consisting of IMP449, IMP460, IMP461, IMP467, IMP469, IMP470, IMP471, IMP479, IMP485, IMP486, IMP487, IMP488, IMP490, IMP493, IMP495, IMP497, IMP500, IMP508 and IMP517.